MedX Health Corp. (TSX-V:MDX) has announced a memorandum of understanding with the London Medical Laboratory Ltd on a commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure Screening Platform in the UK.
The medical device and software company which focuses on skin health said the pilot will span three to six months and will involve an estimated 1,000 patients in London. Upon the successful completion of the pilot, the MedX DermSecure platform will be made available at several new centers across the UK and Ireland, it added.
“With melanoma skin cancer rates more than doubling in the UK since the 1990s, our partnership with London Medical Laboratory presents an enormous opportunity to improve patient outcomes,” MedX CEO Sylvain Desjeans said in a statement.
“Agreements like this ensure we can maximize our growth potential and realize our purpose of saving lives,” he added.
READ: MedX Health positioned for a strong 2022, new CEO says as the company reports 3Q results
MedX said the agreement is the latest in a series of commercialization pilots recently launched across Europe and the Middle East as part of its global commercialization strategy, building on pilots underway in the Netherlands, Italy, Turkey and United Arab Emirates. Additionally, it said commercialization pilots are anticipated in the coming months.
“At London Medical Laboratory, we were seeking a world-class, innovative teledermatology partner for our patients and we found such a partner in MedX – their image capture system is the best available on the market today,” London Medical Laboratory Ltd CEO Seth Rankin said.
“We look forward to working with MedX to make this leading technology available to the UK patients who need it most.”
MedX noted that, according to Cancer Research UK, melanoma skin cancer incidence rates have increased by 140% since the 1990s and have almost tripled for males during this time.
The incidence rate is projected to grow an additional 7% by 2035, with approximately 16,700 new cases diagnosed each year. Early and rapid detection of melanoma is key to improving patient outcomes.
“This pilot is a critical first step to establishing our presence in a market of more than 68 million people,” said Naman Demaghlatrous, MedX managing director of Europe, Middle East and Africa.
“Given the increasing incidence rate of melanoma in the UK, we will continue to seek additional opportunities to grow our presence throughout the UK and Ireland in the months to come.”
Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist.
MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process.
MedX’s SIAscopy is the only technology in the world that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin’s surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within just 72 hours.
Contact the author at stephen.gunnion@proactiveinvestors.com